XML 20 R3.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 28, 2024
Dec. 30, 2023
Dec. 31, 2022
Total revenue $ 4,049,989 $ 4,129,409 $ 3,976,060
Costs and expenses      
Selling, general and administrative 751,003 747,855 665,098
Amortization of intangible assets 138,471 137,440 146,578
Goodwill impairment 215,000 0 0
Operating income 227,347 617,261 650,975
Other income (expense)      
Interest income 8,575 5,196 780
Interest expense (126,288) (136,710) (59,291)
Other income (expense), net (16,520) 95,537 30,523
Income before income taxes 93,114 581,284 622,987
Provision for income taxes 67,823 100,914 130,379
Net income 25,291 480,370 492,608
Less: Net income attributable to noncontrolling interests 3,088 5,746 6,382
Net income attributable to Charles River Laboratories International Inc. 22,203 474,624 486,226
Calculation of net income per share attributable to Charles River Laboratories International Inc. common shareholders      
Net income attributable to Charles River Laboratories International Inc. 22,203 474,624 486,226
Less: Incremental dividends attributed to noncontrolling interest holders 11,906 0 0
Net income available to Charles River Laboratories International Inc. common shareholders $ 10,297 $ 474,624 $ 486,226
Earnings per common share      
Basic (in dollars per share) $ 0.20 $ 9.27 $ 9.57
Diluted (in dollars per share) $ 0.20 $ 9.22 $ 9.48
Weighted-average number of common shares outstanding      
Basic (in shares) 51,380 51,227 50,812
Diluted (in shares) 51,628 51,451 51,301
Service      
Total revenue $ 3,304,138 $ 3,440,019 $ 3,216,904
Costs and expenses      
Cost of revenue (excluding amortization of intangible assets) 2,345,781 2,295,983 2,143,318
Product      
Total revenue 745,851 689,390 759,156
Costs and expenses      
Cost of revenue (excluding amortization of intangible assets) $ 372,387 $ 330,870 $ 370,091